• 1
    Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996;14:10018.
  • 2
    Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14:6779.
  • 3
    Griffiths E, Sierra G, Holst J. Quality control of the Cuban and Norwegian serogroup B vaccines used in the Icelandic study. In: Evans JS, Yost SE, Maiden MCJ, Feavers IM, eds. Neisseria 94. Proceedings of the Ninth International Pathogenic Neisseria Conference.Winchester, England: SCC, 1994:437.
  • 4
    Holst J, Feiring B, Naess LM et al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005;23:22025.
  • 5
    Fredriksen JH, Griffiths E, Grotterød EM, Høiby EA, Rosenqvist E, Stevenson P. Characterization of high molecular weight components in MenB vaccine “Folkehelsa”; an outer membrane vesicle vaccine against group B meningococcal disease. In: Conde-Glez CJ, Morse S, Rice P, Sparling F, Calderon E, eds. Pathobiology and Immunology of Neisseriaceae. Cuernavaca: Instituto Nacional de Salud Publica, 1994:81824. ISBN: 968-6502-13-0.
  • 6
    Norheim G, Aase A, Caugant DA et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005;23:376274.
  • 7
    Peeters CC, Claassen IJ, Schuller M, Kersten GF, van der Voort EM, Poolman JT. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine 1999;17:270212.
  • 8
    Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006;13:48691.
  • 9
    Peeters CC, Rumke HC, Sundermann LC et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:100915.
  • 10
    Rosenqvist E, Hoiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:464252.
  • 11
    Wedege E, Froholm LO. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 1986;51:5718.
  • 12
    Wedege E, Hoiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998;66:322331.
  • 13
    Wedege E, Bolstad K, Aase A et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 2007;14:8308.
  • 14
    Borrow R, Carlone GM, Rosenstein N et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006;24:5093107.
  • 15
    Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27 (Suppl. 2):B1126.
  • 16
    Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007;75:543442.
  • 17
    Manning DS, Reschke DK, Judd RC. Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87. Microb Pathog 1998;25:1121.
  • 18
    Loosmore SM, Yang YP, Coleman DC, Shortreed JM, England DM, Klein MH. Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease. Infect Immun 1997;65:37017.
  • 19
    Ruffolo CG, Adler B. Cloning, sequencing, expression, and protective capacity of the oma87 gene encoding the Pasteurella multocida 87-kilodalton outer membrane antigen. Infect Immun 1996;64:31617.
  • 20
    Thomas KL, Leduc I, Olsen B, Thomas CE, Cameron DW, Elkins C. Cloning, overexpression, purification, and immunobiology of an 85-kilodalton outer membrane protein from Haemophilus ducreyi. Infect Immun 2001;69:443846.
  • 21
    Yang Y, Thomas WR, Chong P, Loosmore SM, Klein MH. A 20-kilodalton N-terminal fragment of the D15 protein contains a protective epitope(s) against Haemophilus influenzae type a and type b. Infect Immun 1998;66:334954.
  • 22
    Voulhoux R, Bos MP, Geurtsen J, Mols M, Tommassen J. Role of a highly conserved bacterial protein in outer membrane protein assembly. Science 2003;299:2625.
  • 23
    Voulhoux R, Tommassen J. Omp85, an evolutionarily conserved bacterial protein involved in outer-membrane-protein assembly. Res Microbiol 2004;155:12935.
  • 24
    Kozjak V, Wiedemann N, Milenkovic D et al. An essential role of Sam50 in the protein sorting and assembly machinery of the mitochondrial outer membrane. J Biol Chem 2003;278:485203.
  • 25
    Paschen SA, Waizenegger T, Stan T et al. Evolutionary conservation of biogenesis of beta-barrel membrane proteins. Nature 2003;426:8626.
  • 26
    Reumann S, Davila-Aponte J, Keegstra K. The evolutionary origin of the protein-translocating channel of chloroplastic envelope membranes: identification of a cyanobacterial homolog. Proc Natl Acad Sci U S A 1999;96:7849.
  • 27
    Weynants V, Denoel P, Devos N et al. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 2009;77:208493.
  • 28
    Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 1979;9:1868.
  • 29
    Steller S, Angenendt P, Cahill DJ, Heuberger S, Lehrach H, Kreutzberger J. Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics 2005;5:204855.
  • 30
    Bussow K, Cahill D, Nietfeld W et al. A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. Nucleic Acids Res 1998;26:50078.
  • 31
    Pagotto FJ, Salimnia H, Totten PA, Dillon JR. Stable shuttle vectors for Neisseria gonorrhoeae, Haemophilus spp. and other bacteria based on a single origin of replication. Gene 2000;244:139.
  • 32
    Frasch CE, van Alphen L, Holst J, Poolman J, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MCJ, eds. Meningococcal Vaccines: Methods and Protocols. Totowa, New Jersey: Humana Press, 2001:81107. ISBN: 0-89603-801-7.
  • 33
    Tsolakos N, Lie K, Bolstad K et al. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine 2010;28:32118.
  • 34
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:6805.
  • 35
    Wedege E. Immunoblot analysis of sera from patients and vaccinees. In: Pollard AJ, Maiden MCJ, eds. Meningococcal Vaccines: Methods and Protocols. Totowa, New Jersey: Humana Press, 2001:27588. ISBN: 0-89603-801-7.
  • 36
    Aase A, Naess LM, Sandin RH et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 2003;21:204251.
  • 37
    de Jonge MI, Vidarsson G, van Dijken HH et al. Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis. Infect Immun 2003;71:233140.
  • 38
    Jolley KA, Appleby L, Wright JC, Christodoulides M, Heckels JE. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect Immun 2001;69:380916.
  • 39
    Musacchio A, Carmenate T, Delgado M, Gonzalez S. Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. Vaccine 1996;15:7518.
  • 40
    Rosenqvist E, Hoiby EA, Wedege E, Kusecek B, Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis 1993;167:106573.
  • 41
    Genevrois S, Steeghs L, Roholl P, Letesson JJ, van der Ley P. The Omp85 protein of Neisseria meningitidis is required for lipid export to the outer membrane. EMBO J 2003;22:17809.
  • 42
    Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009;27 (Suppl. 2):B11725.
  • 43
    Idanpaan-Heikkila I, Muttilainen S, Wahlstrom E et al. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine 1995;13:15018.
  • 44
    Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004;22:4606.
  • 45
    Martin RM, Lew AM. Is IgG2a a good Th1 marker in mice? Immunol Today 1998;19:49.
  • 46
    Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:27318.
  • 47
    Wedege E, Michaelsen TE. Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine. J Clin Microbiol 1987;25:134953.
  • 48
    Wedege E, Bolstad K, Wetzler LM, Guttormsen H. IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements. J Immunol Methods 2000;244:915.
  • 49
    Sjursen H, Wedege E, Rosenqvist E et al. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination. APMIS 1990;98:10619.
  • 50
    Mandrell RE, Zollinger WD. Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins. J Immunol Methods 1984;67:111.
  • 51
    Wedege E, Bryn K, Froholm LO. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J Immunol Methods 1988;113:519.
  • 52
    Saukkonen K, Leinonen M, Abdillahi H, Poolman JT. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989;7:3258.
  • 53
    van de Waterbeemd B, Streefland M, van der Ley P et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 2010;28:48106.
  • 54
    Pinto VB, Moran EE, Cruz F et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 2011;29:77528.
  • 55
    Zollinger WD, Donets MA, Schmiel DH et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010;28:505767.
  • 56
    Christodoulides M, Brooks JL, Rattue E, Heckels JE. Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 1998;144 (Pt 11):302737.
  • 57
    Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine 2011;29:196873.
  • 58
    Su YC, Wan KL, Mohamed R, Nathan S. Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice. Vaccine 2010;28:500511.
  • 59
    Egan AM, Gordon DL. Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect Immun 1996;64:49529.
  • 60
    Lazar Adler NR, Govan B, Cullinane M, Harper M, Adler B, Boyce JD. The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease? FEMS Microbiol Rev 2009;33:107999.